The Heparin-Induced Thrombocytopenia (HIT) Treatment Market Size is valued at USD 9.38 billion in 2023 and is predicted to reach USD 13.55 billion by the year 2031 at a 4.81% CAGR during the forecast period for 2024-2031.
Heparin-induced thrombocytopenia refers to a complication, such as pulmonary embolism, acute myocardial infarction, deep venous thrombotic stroke, etc., that can occur in patients due to taking heparin products. Hence, the adoption of Heparin-Induced Thrombocytopenia is expected to increase in the near future as concerns grow over the adverse reaction of the drug by the antibody generation.
The growing adoption of heparin, an anticoagulant for cardiovascular and orthopaedic treatment surgery, is expected to drive the growth of the global Heparin-Induced Thrombocytopenia market. The rising usage of heparin in acute coronary syndromes, venous thromboembolism, atrial fibrillation, and dialysis are some of the other factors likely to augment the target market growth. The increasing research and investment in heparin-induced thrombocytopenia globally are expected to push the market expansion in the coming years.
Nevertheless, the substantial expense associated with heparin-induced thrombocytopenia, together with the COVID-19 pandemic, are elements that may restrict the expansion of the target market throughout the projection period. Moreover, the escalation of R&D activities, governmental initiatives promoting heparin usage, and investments from leading entities are anticipated to generate substantial revenue growth potential for participants in the worldwide Heparin-Induced Thrombocytopenia market over the forecast period.
The Heparin-Induced Thrombocytopenia market is segmented on the basis of drug types, test types, and end users. The drug types segment includes lepirudin, danaparoid, and argatroban. By test types, the market is segmented into enzyme immunoassay (EIA), Serotonin Release Assay (SRA), enzyme-linked immunosorbent assay (ELISA), and heparin-induced platelet activation (HIPA) test. By end user, the market is segmented into hospitals, diagnostic centres, specialized clinics, hospital pharmacies, home care settings, and mail-order pharmacies.
The argatroban category is expected to hold a major share of the global Heparin-Induced Thrombocytopenia market in 2023. This is attributed to new product introductions, a rise in the adoption of argatroban with thrombosis and heparin-induced thrombocytopenia. Additionally, argatroban is given intravenously, absorbed in the liver, and has a half-life of about 50 min due to its hepatic absorption. It is used in patients with renal dysfunction.
The hospital pharmacy segment is estimated to grow at a rapid rate in the global Heparin-Induced Thrombocytopenia market owing to growing concerns for patients with HIT; hospitals and healthcare sectors are well-equipped. Hence, the growing cases of HIT require special diagnosis, prompt treatment, and constant monitoring to support the growth of the market. Heparin-induced thrombocytopenia in the hospital pharmacy offers the required infrastructure, equipment, and experienced healthcare professionals.
The North American heparin-induced Thrombocytopenia market is expected to report the highest market share in the near future. This can be attributed to the strong focus on HIT patients in the region, with the increasing adoption of Heparin-Induced Thrombocytopenia for the treatment of different disorders. In addition, the increasing number of patients who have recently received dialysis is focusing on the development of Heparin-Induced Thrombocytopenia in the region. In addition, Asia Pacific is estimated to grow at a rapid rate in the global Heparin-Induced Thrombocytopenia market due to growing concerns about HIT patients, increasing research activities, government initiatives, and increasing funding in various industries.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 9.38 Bn |
|
Revenue Forecast In 2031 |
USD 13.55 Bn |
|
Growth Rate CAGR |
CAGR of 4.81% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Drug Type, Test Type and End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Pfizer Inc., Alleviare Life Sciences Pvt. Ltd., ANDOZ, GlaxoSmithKline Plc., Eagle Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., WEST-WARD, Inc. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Snapshot
Chapter 4. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Heparin-Induced Thrombocytopenia (HIT) Treatment Industry Trends
Chapter 5. Heparin-Induced Thrombocytopenia (HIT) Treatment Market Segmentation 1: By Drug Types, Estimates & Trend Analysis
5.1. Market Share by Drug Types, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Drug Types:
5.2.1. Lepirudin
5.2.2. Danaparoid
5.2.3. Argatroban
Chapter 6. Heparin-Induced Thrombocytopenia (HIT) Treatment Market Segmentation 2: By Test Types, Estimates & Trend Analysis
6.1. Market Share by Test Types, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Test Types:
6.2.1. Enzyme Immunoassay (EIA)
6.2.2. Serotonin Release Assay (SRA)
6.2.3. Enzyme-Linked Immunosorbent Assay (ELISA)
6.2.4. Heparin-Induced Platelet Activation (HIPA) Test
Chapter 7. Heparin-Induced Thrombocytopenia (HIT) Treatment Market Segmentation 3: By End User, Estimates & Trend Analysis
7.1. Market Share by End User, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End Users:
7.2.1. Hospitals
7.2.2. Diagnostic Centers
7.2.3. Specialized Clinics
7.2.4. Hospital Pharmacy
7.2.5. Home Care Setting0073
7.2.6. Mail Order Pharmacy
Chapter 8. Heparin-Induced Thrombocytopenia (HIT) Treatment Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. Global Heparin-Induced Thrombocytopenia (HIT) Treatment Market, Regional Snapshot 2023 & 2031
8.2. North America
8.2.1. North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.2.1.1. US
8.2.1.2. Canada
8.2.2. North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Types, 2024-2031
8.2.3. North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Test Types, 2024-2031
8.2.4. North America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
8.3. Europe
8.3.1. Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.3.1.1. Germany
8.3.1.2. U.K.
8.3.1.3. France
8.3.1.4. Italy
8.3.1.5. Spain
8.3.1.6. Rest of Europe
8.3.2. Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Types, 2024-2031
8.3.3. Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Test Types, 2024-2031
8.3.4. Europe Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
8.4. Asia Pacific
8.4.1. Asia Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.4.1.1. India
8.4.1.2. China
8.4.1.3. Japan
8.4.1.4. Australia
8.4.1.5. South Korea
8.4.1.6. Hong Kong
8.4.1.7. Southeast Asia
8.4.1.8. Rest of Asia Pacific
8.4.2. Asia Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Types, 2024-2031
8.4.3. Asia Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts By Test Types, 2024-2031
8.4.4. Asia Pacific Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
8.5. Latin America
8.5.1. Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
8.5.1.1. Brazil
8.5.1.2. Mexico
8.5.1.3. Rest of Latin America
8.5.2. Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Types, 2024-2031
8.5.3. Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Test Types, 2024-2031
8.5.4. Latin America Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
8.6. Middle East & Africa
8.6.1. Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
8.6.1.1. GCC Countries
8.6.1.2. Israel
8.6.1.3. South Africa
8.6.1.4. Rest of Middle East and Africa
8.6.2. Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Drug Types, 2024-2031
8.6.3. Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by Test Types, 2024-2031
8.6.4. Middle East & Africa Heparin-Induced Thrombocytopenia (HIT) Treatment Market Revenue (US$ Million) Estimates and Forecasts by End User, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Pfizer Inc.
9.2.1.1. Business Overview
9.2.1.2. Key Product/Service Offerings
9.2.1.3. Financial Performance
9.2.1.4. Geographical Presence
9.2.1.5. Recent Developments with Business Strategy
9.2.2. Alleviare Life Sciences Pvt. Ltd.
9.2.3. GlaxoSmithKline Plc.
9.2.4. Eagle Pharmaceuticals Inc.
9.2.5. Teva Pharmaceutical Industries Ltd.
9.2.6. WEST-WARD, INC
9.2.7. Fresenius Kabi AG,
9.2.8. Syntex S.A.,
9.2.9. Celgene Corporation,
9.2.10. Diapharma
9.2.11. Eisai Co., Ltd,
9.2.12. LEO Pharma A/S
9.2.13. Mylan N.V.
9.2.14. Sanofi S.A.
9.2.15. Other Prominent Players
Heparin-Induced Thrombocytopenia Market By Drug Types-
Heparin-Induced Thrombocytopenia Market By Test Types-
Heparin-Induced Thrombocytopenia Market By End User-
Heparin-Induced Thrombocytopenia Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
